JP2022500464A - Her2+癌および他の新生物の標的放射性核種治療および分子イメージング及び精密治療 - Google Patents
Her2+癌および他の新生物の標的放射性核種治療および分子イメージング及び精密治療 Download PDFInfo
- Publication number
- JP2022500464A JP2022500464A JP2021514616A JP2021514616A JP2022500464A JP 2022500464 A JP2022500464 A JP 2022500464A JP 2021514616 A JP2021514616 A JP 2021514616A JP 2021514616 A JP2021514616 A JP 2021514616A JP 2022500464 A JP2022500464 A JP 2022500464A
- Authority
- JP
- Japan
- Prior art keywords
- her2
- cancer
- tumor
- integrin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 366
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title claims abstract description 328
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title claims abstract description 327
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 14
- 201000011510 cancer Diseases 0.000 title claims description 110
- 238000003384 imaging method Methods 0.000 title claims description 17
- 238000011361 targeted radionuclide therapy Methods 0.000 title description 75
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 116
- 238000011282 treatment Methods 0.000 claims abstract description 111
- 108010044426 integrins Proteins 0.000 claims abstract description 104
- 102000006495 integrins Human genes 0.000 claims abstract description 104
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 90
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 89
- 238000000034 method Methods 0.000 claims abstract description 84
- 239000000203 mixture Substances 0.000 claims abstract description 83
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims abstract description 32
- 238000003745 diagnosis Methods 0.000 claims abstract description 27
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 15
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 13
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 12
- 230000002285 radioactive effect Effects 0.000 claims abstract description 12
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 7
- 230000008472 epithelial growth Effects 0.000 claims abstract description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 6
- 102000009465 Growth Factor Receptors Human genes 0.000 claims abstract description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 claims abstract description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 4
- -1 3,4,5,6-tetrahydropyrimidine-2-ylamino Chemical group 0.000 claims description 51
- 230000001225 therapeutic effect Effects 0.000 claims description 43
- 229940123038 Integrin antagonist Drugs 0.000 claims description 38
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 37
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 37
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 34
- 239000005557 antagonist Substances 0.000 claims description 30
- 239000002738 chelating agent Substances 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 29
- 206010027476 Metastases Diseases 0.000 claims description 28
- 230000002401 inhibitory effect Effects 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 230000009401 metastasis Effects 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 229940000635 beta-alanine Drugs 0.000 claims description 19
- 230000037361 pathway Effects 0.000 claims description 19
- 210000004881 tumor cell Anatomy 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 17
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 17
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 17
- 229960000575 trastuzumab Drugs 0.000 claims description 17
- 230000033115 angiogenesis Effects 0.000 claims description 16
- 230000012010 growth Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000006850 spacer group Chemical group 0.000 claims description 15
- 230000004614 tumor growth Effects 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 12
- 230000008685 targeting Effects 0.000 claims description 12
- 229940125666 actinium-225 Drugs 0.000 claims description 11
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
- 208000032612 Glial tumor Diseases 0.000 claims description 10
- 206010018338 Glioma Diseases 0.000 claims description 10
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 10
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 claims description 10
- PTLFKOKFIWCOPF-UHFFFAOYSA-N OC(=O)CCNN=S(=O)=O Chemical class OC(=O)CCNN=S(=O)=O PTLFKOKFIWCOPF-UHFFFAOYSA-N 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 208000001132 Osteoporosis Diseases 0.000 claims description 9
- 150000001413 amino acids Chemical group 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 9
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 claims description 9
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 6
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical compound [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 claims description 6
- 102000008607 Integrin beta3 Human genes 0.000 claims description 5
- 108010020950 Integrin beta3 Proteins 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 239000012216 imaging agent Substances 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- QVFLVLMYXXNJDT-CSBVGUNJSA-N (2s,3r)-2-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[[(2r)-3-phenyl-2-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]pro Chemical compound C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C1=CC=CC=C1 QVFLVLMYXXNJDT-CSBVGUNJSA-N 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
- 238000002059 diagnostic imaging Methods 0.000 claims description 4
- 229940010982 dotatate Drugs 0.000 claims description 4
- 229960002087 pertuzumab Drugs 0.000 claims description 4
- 230000000250 revascularization Effects 0.000 claims description 4
- 230000004565 tumor cell growth Effects 0.000 claims description 4
- 229940123776 Immuno-oncology therapy Drugs 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 claims description 3
- 201000000053 blastoma Diseases 0.000 claims description 3
- 201000008184 embryoma Diseases 0.000 claims description 3
- 210000005102 tumor initiating cell Anatomy 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 230000002301 combined effect Effects 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 229950008835 neratinib Drugs 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 2
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 238000011362 radionuclide therapy Methods 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 48
- 102000004169 proteins and genes Human genes 0.000 abstract description 41
- 239000003814 drug Substances 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 22
- 238000002512 chemotherapy Methods 0.000 abstract description 19
- 210000004556 brain Anatomy 0.000 abstract description 15
- 108010031318 Vitronectin Proteins 0.000 abstract description 13
- 102100035140 Vitronectin Human genes 0.000 abstract description 13
- 108010067306 Fibronectins Proteins 0.000 abstract description 11
- 102100037362 Fibronectin Human genes 0.000 abstract description 10
- MQOMKCIKNDDXEZ-UHFFFAOYSA-N 1-dibutylphosphoryloxy-4-nitrobenzene Chemical compound CCCCP(=O)(CCCC)OC1=CC=C([N+]([O-])=O)C=C1 MQOMKCIKNDDXEZ-UHFFFAOYSA-N 0.000 abstract description 7
- 101000713211 Colocasia esculenta Mannose-specific lectin TAR1 Proteins 0.000 abstract description 7
- 241000104952 Xanthophyllum eurhynchum Species 0.000 abstract description 7
- 241000894007 species Species 0.000 abstract description 7
- 108010008125 Tenascin Proteins 0.000 abstract description 4
- 102000007000 Tenascin Human genes 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 238000002619 cancer immunotherapy Methods 0.000 abstract description 4
- 206010062878 Gastrooesophageal cancer Diseases 0.000 abstract description 2
- 201000006974 gastroesophageal cancer Diseases 0.000 abstract description 2
- 229910052751 metal Inorganic materials 0.000 abstract description 2
- 239000002184 metal Substances 0.000 abstract description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 39
- 108700038365 Reelin Proteins 0.000 description 27
- 102000043322 Reelin Human genes 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 239000002246 antineoplastic agent Substances 0.000 description 23
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 17
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 17
- 210000000481 breast Anatomy 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 238000002600 positron emission tomography Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 description 11
- 210000001130 astrocyte Anatomy 0.000 description 11
- 239000002287 radioligand Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000008595 infiltration Effects 0.000 description 10
- 238000001764 infiltration Methods 0.000 description 10
- 206010061289 metastatic neoplasm Diseases 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000001394 metastastic effect Effects 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000002458 carcinoid tumor Diseases 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 6
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 229910052765 Lutetium Inorganic materials 0.000 description 5
- 206010059282 Metastases to central nervous system Diseases 0.000 description 5
- 108050001286 Somatostatin Receptor Proteins 0.000 description 5
- 102000011096 Somatostatin receptor Human genes 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 230000001973 epigenetic effect Effects 0.000 description 5
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 239000012217 radiopharmaceutical Substances 0.000 description 5
- 229940121896 radiopharmaceutical Drugs 0.000 description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000011272 standard treatment Methods 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 4
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 4
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000009206 nuclear medicine Methods 0.000 description 4
- 208000028591 pheochromocytoma Diseases 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000000163 radioactive labelling Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 3
- 206010018404 Glucagonoma Diseases 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 3
- 108091027977 Mir-200 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010041329 Somatostatinoma Diseases 0.000 description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229910052767 actinium Inorganic materials 0.000 description 3
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 208000035850 clinical syndrome Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000003236 esophagogastric junction Anatomy 0.000 description 3
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 3
- 201000000052 gastrinoma Diseases 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 229940116978 human epidermal growth factor Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 206010022498 insulinoma Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 238000009099 neoadjuvant therapy Methods 0.000 description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000014187 peptide receptors Human genes 0.000 description 3
- 108010011903 peptide receptors Proteins 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 229940056501 technetium 99m Drugs 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- MXDPZUIOZWKRAA-PRDSJKGBSA-K 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(1s,2r)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-y Chemical compound [177Lu+3].C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1)C1=CC=CC=C1 MXDPZUIOZWKRAA-PRDSJKGBSA-K 0.000 description 2
- ZCXUVYAZINUVJD-UKFBFLRUSA-N 2-deoxy-2-fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](F)[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-UKFBFLRUSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000028112 ACTH-producing pituitary gland adenoma Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100022337 Integrin alpha-V Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108010070047 Notch Receptors Proteins 0.000 description 2
- 102000005650 Notch Receptors Human genes 0.000 description 2
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 101150058540 RAC1 gene Proteins 0.000 description 2
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 2
- 102000006463 Talin Human genes 0.000 description 2
- 108010083809 Talin Proteins 0.000 description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- 208000009311 VIPoma Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical class 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 102000051957 human ERBB2 Human genes 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 108700033205 lutetium Lu 177 dotatate Proteins 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108091089775 miR-200b stem-loop Proteins 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000011242 molecular targeted therapy Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000017511 neuron migration Effects 0.000 description 2
- 230000007511 neuronal proliferation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- VXZCUHNJXSIJIM-MEBGWEOYSA-N (z)-but-2-enedioic acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound OC(=O)\C=C/C(O)=O.C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 VXZCUHNJXSIJIM-MEBGWEOYSA-N 0.000 description 1
- QUHGSDZVAPFNLV-UHFFFAOYSA-N 4-[(5-acetamidofuran-2-carbonyl)amino]-n-[3-(dimethylamino)propyl]-1-propylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCCN(C)C)N(CCC)C=C1NC(=O)C1=CC=C(NC(C)=O)O1 QUHGSDZVAPFNLV-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000004373 Actin-related protein 2 Human genes 0.000 description 1
- 108090000963 Actin-related protein 2 Proteins 0.000 description 1
- 206010001150 Adenocarcinoma gastric Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010057654 Breast cancer female Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100447914 Caenorhabditis elegans gab-1 gene Proteins 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025051 Cell division control protein 42 homolog Human genes 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 description 1
- 239000012626 DNA minor groove binder Substances 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000829127 Homo sapiens Somatostatin receptor type 2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 229940127449 Integrin Receptor Antagonists Drugs 0.000 description 1
- 108010040765 Integrin alphaV Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 229940127049 Lutathera Drugs 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 241001118798 Serendipita Species 0.000 description 1
- 102100023802 Somatostatin receptor type 2 Human genes 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011347 external beam therapy Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- IWPSJDKRBIAWLY-UHFFFAOYSA-N gallium zirconium Chemical compound [Ga].[Zr] IWPSJDKRBIAWLY-UHFFFAOYSA-N 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000014200 hypermethylation of CpG island Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960001320 lapatinib ditosylate Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108700009084 lexitropsin Proteins 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 229940008393 lutetium lu 177 dotatate Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 239000002667 nucleating agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940072272 sandostatin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- ASXRRCSNWSZWHO-UHFFFAOYSA-N tert-butyl 2-(1,4,7-triazonan-1-yl)acetate Chemical compound CC(C)(C)OC(=O)CN1CCNCCNCC1 ASXRRCSNWSZWHO-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本出願は平成30年9月11日に出願された米国仮出願第62/729,959号の優先権の利益を主張し、その全内容は、参照により本明細書に組み込まれる。
免疫療法の副作用
腫瘍標的放射性核種療法(TRNT)
治療方法
実施例6:患者は実施例5と同様に治療されたが、キレート剤は以下のうちの1つ以上を含む:4−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ)エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)及び(ii)下記の少なくとも一つ:
(a)1−(1−カルボキシ−3−カルボテルトブトキシメチル)−1,4,7,10−テトラアザシクロドデカン(DOTAGA)(tBu)sub.4;
(b)4−[4,7−ビス−(カルボキシメチル)−[1,4,7]トリアゾナン−1−イル]−4−カルボキシ−ブチリル(NODAGA);
(c)ドータテート
(d)C26H34N4O10S(CHX−A)。
キンドリン(又は、Kindlin)
Claims (65)
- ヒト上皮成長因子受容体2ポジティブ(以下、HER2+と呼ぶ)、またはインテグリン受容体を医薬組成物で過剰発現する他の癌を有する患者を治療するための方法であって、
分子構造がスルホニルアミノ−β−アラニン核上にテトラヒドロピリジミジニル−アミノエチルオキシベンゾイル基を含み、スルホニル部分上でN−アミノアルキルカルバミル基またはブチルオキシカルボニルアミノアルキルカルバモイル基またはキレート剤を有する類似の基でさらに置換したときに、α5β3(以下、β3と呼ぶ)インテグリン受容体に対して選択的で高い結合親和性を示す薬理学的に有効量のインテグリンのアンタゴニストペプチドミメティック化合物と、
腫瘍標的β3ペプチドミメティック受容体放射性核種治療(以下、TRNTと呼ぶ)のための診断または治療用放射性核種
の組合せを前記患者に投与することを含む方法。 - 前記インテグリンのアンタゴニストペプチドミメティック化合物が、Lu−177 DOTAGA IACからなる、請求項1に記載の方法。
- 活性部分を含有するインテグリンリガンドの前記アンタゴニストペプチドミメティック化合物が1−(1−カルボキシ−3−カルボテルブトキシメチル)−1,4,7,10−テトラアザシクロドデカン(DOTAGA)(tBu.)sub.4に結合し、Lutetium−177で放射線標識されたαVβ3インテグリンアンタゴニストペプチドミメティック4−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ)エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)を含む、請求項2に記載の方法。
- インテグリンのアンタゴニストペプチドミメティック化合物の薬理学的に有効量の前記組み合わせを投与することが、数週間または数ヶ月を含む期間にわたって投薬を繰り返すことを含む、請求項3に記載の方法。
- 癌を有する患者を免疫腫瘍学療法で治療する請求項1記載の方法であって、前記TRNTと多剤レジメンにおける免疫腫瘍学療法との併用効果が前記癌に対する治療効果を生じる、方法。
- 前記患者を免疫腫瘍治療で治療することが、PD−1/PD−L1/CTLA−4阻害剤を含む、請求項5に記載の方法。
- 血管内皮増殖因子受容体タンパク質(以下、VEGFと呼ぶ)を過剰発現する癌を有する患者を治療するための、請求項1に記載の方法であって、前記患者に、TRNTのためのペプチドミメティックと、血管内皮増殖因子を阻害する阻害剤との組合せを投与することを含み、かつ/または、TRNTと血管内皮増殖因子の阻害剤との組合せ効果が前記癌に対する治療効果を生じる、方法。
- 前記癌が、乳癌または胃癌のうちの1つ以上である、請求項1に記載の方法。
- 前記治療が、HER2+腫瘍の増殖を阻害すること、腫瘍細胞の増殖を阻害すること、腫瘍転移を阻害すること、腫瘍細胞の分化を誘導すること、乳癌腫瘍細胞の造腫瘍性を低下させること、および乳癌腫瘍における癌幹細胞または腫瘍開始細胞の頻度を低下させる方法の1つまたは複数を含む、請求項1に記載の方法。
- 前記癌が、カルチノイド腫瘍、脳腫瘍、膵腫瘍、膨大部腫瘍、腺癌、下垂体腺腫、副腎腫瘍、メルケル細胞癌、乳癌、非ホジキンリンパ腫、ホジキンリンパ腫、多発性骨髄腫、頭頸部腫瘍、尿路上皮癌(膀胱)、腎細胞癌、中腸腫瘍、小細胞肺癌、非小細胞肺癌、肝細胞癌、GIST、神経芽腫、胆管腫瘍、子宮頸部腫瘍、ユーイング肉腫、非小細胞肺癌、膵癌、骨肉腫、白血病、前立腺癌、黒色腫、髄膜腫、神経膠腫、髄芽腫、血管芽腫、テント上原始腫瘍、神経外胚葉性腫瘍、肝芽腫または感覚神経芽細胞腫からなる群より選択される腫瘍を含む、請求項1記載の方法。
- 前記癌が応答性トラスツズマブ、アド−トラスツズマブ・エムタンシン、ラパチニブ、ネラチニブ、ペルツズマブまたは他のチロシンキナーゼ阻害剤ではない、請求項1記載の方法。
- 前記癌が、VEGF経路のインヒビターに対して非応答性であるか、または低い応答性を有する、請求項1に記載の方法。
- 前記癌が機能性乳癌腫瘍である、請求項1に記載の方法。
- 前記癌が非機能性乳癌腫瘍である、請求項1に記載の方法。
- VEGFアンタゴニストを投与することをさらに含む、請求項1に記載の方法。
- 活性部分、αVβ3インテグリンアンタゴニストペプチドミメティック、4−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ)エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)を含み、1−(1−カルボキシ−3−カルボ−t−ブトキシプロピル)−4,7−(カルボ−tert−ブトキシメチル)−1,4,7−トリアザシクロノナンに結合され、[68]Gaで放射線標識されたリガンドを含み、コンパニオン診断で前記患者を画像化することを含む、請求項1に記載の方法。
- 前記患者に、前記インテグリンのアンタゴニストペプチドミメティック化合物の薬理学的有効量の組み合わせを投与すること、および前記コンパニオン診断を施し、PET、SPECTおよびMRIのうちの1つ以上を使用して前記患者をスキャンすることによって、前記患者を画像化すること、および前記インテグリンのアンタゴニストペプチドミメティック化合物の薬理学的有効量を用いて、前記投与された治療の有効性を決定することを含む、請求項16に記載の方法。
- 哺乳動物被験体における癌の存在、転移、または病期分類を決定するための方法であって、
(a)前記哺乳動物被験体に、活性部分、αVβ3インテグリンアンタゴニストペプチドミメティック、4−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ)エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)を含み、1−(1−カルボキシ−3−カルボキシ−t−ブトキシプロピル)−4,7−(カルボ−tert−ブトキシメチル)−1,4,7−トリアザシクロノナンと結合され、[68]Gaで放射線標識された有効量のリガンドを投与し、
(b)PET、SPECT、およびMRIのうちの1つまたは複数を使用して被験者をスキャンし、
(c)前記スキャンから、転移または血管新生に関連する1以上の疾患の存在を診断することを含み、
前記1以上の疾患は、乳癌、肺癌、卵巣癌、胃癌、食道癌、血液媒介癌、筋骨格腫瘍、黒色腫、頭頸部癌、ヒト神経膠腫、子宮頸癌、血管再狭窄、骨粗鬆症、および関節リウマチからなる群から選択される、方法。 - 転移または血管新生に関連する前記1つ以上の疾患の存在が前記スキャンから診断される場合、
分子構造がスルホニルアミノ−β−アラニン核上にテトラヒドロピリジミジニル−アミノエチルオキシベンゾイル基を含み、スルホニル部分上でN−アミノアルキルカルバミル基またはブチルオキシカルボニルアミノアルキルカルバモイル基またはキレート剤を有する類似の基でさらに置換したときに、α5β3(以下、β3と呼ぶ)インテグリン受容体に対して選択的で高い結合親和性を示す薬理学的に有効な量のインテグリンアンタゴニストペプチドミメティック化合物と、
腫瘍標的β3ペプチドミメティック受容体放射性核種治療のための診断または治療用放射性核種(以下、TRNTと称される)
の組み合わせを前記患者に投与することを含む、請求項18に記載の方法。 - ヒト上皮成長因子受容体2ポジティブ(以下、HER2+と呼ぶ)、またはインテグリン受容体を過剰発現する他の癌を標的化および治療するための治療および診断用医薬組成物であって、
分子構造がスルホニルアミノ−β−アラニン核上にテトラヒドロピリジミジニル−アミノエチルオキシベンゾイル基を含み、α5β3に対して選択的かつ高結合親和性を示すインテグリンを含むαvβ3/αvβ5抗インテグリンアンタゴニストペプチドミメティック、
少なくとも1つの放射性核種、及び
スペーサシーケンス
を含み、
前記インテグリンはスペーサシーケンスによって共有結合され、
キレート剤はNODAGA、DOTAGA、DOTATATE、DOTATATE、CHX−A及び薬学的に許容される賦形剤からなる群より選択される、医薬組成物。 - 前記スペーサシーケンスが線状人工シーケンスである、請求項20に記載の治療および診断組成物。
- 前記放射性核種が、ルテチウム−177、アクチニウム−225、ビスマス−213、トリウム−227、鉛−212、アスタチン−211、イットリウム−90、およびヨウ素−131からなる群より選択される、請求項20に記載の治療および診断用組成物。
- 放射性核種がルテチウム−177からなる群から選択される、請求項20に記載の治療および診断用組成物。
- 放射性核種がアクチニウム−225からなる群から選択される、請求項22に記載の治療用および診断用組成物。
- 前記放射性核種がLu−177であり、前記キレート剤がDOTAGAであり、前記活性部分が[177Lu]DOTAGA IACからなる、請求項20に記載の治療用組成物。
- 前記スペーサシーケンスが、前記キレート剤と、スルホニルアミノ−β−アラニン核上の前記テトラヒドロピリジミジニル−アミノエチルオキシベンゾイル基との間に提供され、α5β3に対して選択的で高い結合親和性を示す、請求項20に記載の治療および診断用組成物。
- 前記キレート剤がDOTAGAである、請求項20に記載の治療用および診断用組成物。
- 前記キレート剤がNODAGAである、請求項20に記載の治療用および診断用組成物。
- 前記キレート剤がドータテートである、請求項20に記載の治療用および診断用組成物。
- 前記キレート剤がCHX−Aである、請求項20に記載の治療用および診断用組成物。
- 前記キレート剤がIACも含む、請求項20に記載の治療用および診断用組成物。
- 前記インテグリンアンタゴニストが、放射性核種にキレート化されたペプチドミメティックである、請求項20に記載の治療用および診断用組成物。
- 活性部分4が−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ)エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)を含有する、請求項20に記載の治療および診断用組成物。
- 活性部分がアセチルスルファニル−エトキシ}−エトキシ)−エトキシ]−エトキシ}−プロピオニルアミノ)−プロポキシ]−ベンジル}−ウレイド]−チアゾール−4−カルボニル)−アミノ}−アセチルアミノ]−フェニル−3−イル−プロピオン酸を含有する、請求項20に記載の治療および診断用組成物。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を標的化、診断および治療するための腫瘍標的放射性核種療法(TRNT)のための組成物であって、
(1)活性部分を含むリガンドであって、
αvβ3インテグリンアンタゴニストペプチドミメティックと、
(i)4−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ)エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)及び
(ii)
(a)1−(1−カルボキシ−3−カルボテルトブトキシメチル)−1,4,7,10−テトラアザシクロドデカン(DOTAGA)(tBu)sub.4、又は、
(b)4−[4,7−ビス−(カルボキシメチル)−[1,4,7]トリアゾナン−1−イル]−4−カルボキシ−ブチリル(NODAGA)、又は、
(c)DOTATATE、又は、
(d)C26H34N4O10S(CHX−A)
のいずれかと、
を有するリガンドと、
(2)ルテチウム−177、アクチニウム−225、ビスマス−213、トリウム−227、鉛−212、アスタチン−211、イットリウム−90、ヨウ素−131、または放射性核種の組み合わせからなる群から選択される放射性核種
を含む組成物。 - α5β3に対する結合親和性を有する結合領域を有し、スルホニルアミノ−β−アラニン核上にテトラヒドロピリジミジニル−アミノエチルオキシベンゾイル基を含む、請求項35に記載の組成物。
- 前記αvβ3インテグリンアンタゴニストペプチドミメティックを、(ii)(a)、または(ii)(b)、または(ii)(c)、または(ii)(d)の少なくとも1つに共有結合させるスペーサシーケンスを含む、請求項35に記載の組成物。
- 前記組成物が[177Lu]DOTAGA IACを含む、請求項36に記載の組成物。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を標的化、診断および治療するための腫瘍標的放射性核種療法(TRNT)のための組成物であって、
a)αvβ3インテグリンアンタゴニストペプチドミメティックと、
b)放射性核種を有し、
c)前記放射性核種はスペーサ、キレート化剤に共有結合し、又は、ペプチドミメティックに直接、ナノ粒子に、またはペプチドミメティックの2つ以上のアミノ酸単位に共有結合し、
d)前記組成物は、
(i)4−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ)エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)、
(ii)1−(1−カルボキシ−3−カルボテルトブトキシメチル)−1,4,7,10−テトラアザシクロドデカン(DOTAGA)(tBu)sub.4、
(iii)4−[4,7−ビス−(カルボキシメチル)−[1,4,7]トリアゾナン−1−イル]−4−カルボキシ−ブチリル(NODAGA)、
(iv)ドータテート、又は
(v)C26H34N4O10S(CHX−A)
の1つ以上を含み、前記(i)〜(v) の1つ以上に前記放射性核種がキレート化される、組成物。 - ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を含む癌の存在、増殖または分解を検出する際に使用するための診断用イメージング剤であって、患者に投与された場合に、PET、SPECTおよびMRIのうちの1つ以上を使用して患者をスキャンすることによって癌の存在、増殖または分解を示し、
活性部分、αVβ3インテグリンアンタゴニストペプチドミメティック、4−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ)エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)を含み、1−(1−カルボキシ−3−カルボキシ−t−ブトキシプロピル)−4,7−(カルボ−tert−ブトキシメチル)−1,4,7−トリアザシクロノナンに結合され、[68]Gaで放射線標識したリガンド
を含むイメージング剤。 - ヒト上皮成長因子受容体2ポジティブ(HER2+)を含む癌、またはインテグリン受容体を過剰発現する他の癌を検出するための、請求項40に記載の画像診断薬の使用。
- 癌を治療するためのインテグリンの薬理学的に有効な量のアンタゴニストペプチドミメティック化合物であって、
前記アンタゴニストペプチドミメティックインテグリン化合物は、分子構造がスルホニルアミノ−β−アラニン核上のテトラヒドロピリジミジニル−アミノエチルオキシベンゾイル基を含み、スルホニル部分上でN−アミノアルキルカルバミル基またはブチルオキシカルボニルアミノアルキルカルバモイル基またはキレート剤を有する類似の基でさらに置換したときにα5β3(以下、β3と呼ぶ)インテグリン受容体に対して選択的で高い結合親和性を示す、該アンタゴニストペプチドミメティック化合物と、
腫瘍標的β3ペプチドミメティック受容体放射性核種治療(以下、TRNTと称する)のための診断または治療用放射性核種
の使用。 - ヒト上皮成長因子受容体2ポジティブ(以下HER2+)である癌、またはインテグリン受容体を過剰発現する他の癌の治療のための、治療有効量の放射線標識β3インテグリンアンタゴニストの使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項1に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項2に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項3に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項4に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項5に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための、請求項6に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項7に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項8に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項9に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項10に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項11に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項12に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項13記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための、請求項14に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項15に記載の組成物の使用。
- 活性部分、αVβ3インテグリンアンタゴニストペプチドミメティック4−[2−(3,4,5,6−テトラヒドロピリミジン−2−イルアミノ]エチルオキシ]ベンゾイル−2−[N−(3−アミノネンタ−1−カルバミル)]−アミノエチルスルホニル−アミノ−β−アラニン(IAC)を含み、1−(1−カルボキシ−3−カルボキシ−t−ブトキシプロピル)−4,7−(カルボ−tert−ブトキシメチル)−1,4,7−トリアザシクロノナンに結合され、[68]Gaで放射線標識されたリガンドを含む、インテグリン受容体を過剰発現するヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を検出するためのリガンドの使用、ならびにヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項1〜15のいずれか1項に記載の方法の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害する、請求項20〜34のいずれか一項記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための、請求項35に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項36に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための、請求項37に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための請求項38に記載の組成物の使用。
- ヒト上皮成長因子受容体2ポジティブ(HER2+)、またはインテグリン受容体を過剰発現する他の癌を阻害するための、請求項39の組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862729959P | 2018-09-11 | 2018-09-11 | |
US62/729,959 | 2018-09-11 | ||
PCT/US2019/050705 WO2020056064A1 (en) | 2018-09-11 | 2019-09-11 | Tumor targeted radionuclide therapy and molecular imaging of her2+ cancers and other neoplasms, and precision medicine. |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022500464A true JP2022500464A (ja) | 2022-01-04 |
JPWO2020056064A5 JPWO2020056064A5 (ja) | 2023-05-11 |
Family
ID=69772771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021514616A Pending JP2022500464A (ja) | 2018-09-11 | 2019-09-11 | Her2+癌および他の新生物の標的放射性核種治療および分子イメージング及び精密治療 |
Country Status (4)
Country | Link |
---|---|
US (2) | US11357874B2 (ja) |
EP (1) | EP3923952A4 (ja) |
JP (1) | JP2022500464A (ja) |
WO (1) | WO2020056064A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870389A (zh) * | 2021-01-19 | 2021-06-01 | 德珍(中国)医疗科技有限公司 | 一种与放射性金属复合的DZ-1-Lys-DOTA偶联物及应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830431A (en) | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
US7300940B2 (en) | 2004-08-04 | 2007-11-27 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Integrin α-v β-3 antagonists for use in imaging and therapy |
WO2006133732A1 (en) | 2005-06-17 | 2006-12-21 | Advanced Accelerator Applications | Process for synthesizing labelled compounds |
CA2682064C (en) | 2007-03-27 | 2013-09-24 | Radiomedix Inc. | Compositions for targeted imaging and therapy |
WO2008134618A2 (en) | 2007-04-27 | 2008-11-06 | The General Hospital Corporation | Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders |
GB0821994D0 (en) | 2008-12-02 | 2009-01-07 | Ge Healthcare Ltd | In viva imaging method |
WO2012103328A1 (en) * | 2011-01-26 | 2012-08-02 | The Methodist Hospital Research Institute | Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use |
GB201120586D0 (en) | 2011-11-30 | 2012-01-11 | Ge Healthcare Ltd | Solid phase extraction neutralisation |
JP6316209B2 (ja) | 2012-01-27 | 2018-04-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | αVβ3を発現する細胞への標的化送達のためのインテグリンアンタゴニスト結合体 |
CA2865132A1 (en) | 2012-02-22 | 2013-08-29 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
WO2014029016A1 (en) | 2012-08-24 | 2014-02-27 | University Health Network | Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer |
GB201318450D0 (en) | 2013-10-18 | 2013-12-04 | Ge Healthcare Ltd | Closed evaporation system |
GB201411571D0 (en) | 2014-06-30 | 2014-08-13 | Ge Healthcare Ltd | Radiolabelling method |
-
2019
- 2019-09-11 JP JP2021514616A patent/JP2022500464A/ja active Pending
- 2019-09-11 US US16/568,236 patent/US11357874B2/en active Active
- 2019-09-11 US US16/568,227 patent/US20200085979A1/en not_active Abandoned
- 2019-09-11 WO PCT/US2019/050705 patent/WO2020056064A1/en unknown
- 2019-09-11 EP EP19860439.9A patent/EP3923952A4/en not_active Withdrawn
Non-Patent Citations (3)
Title |
---|
BIOORG. MED. CHEM. LETT., vol. 22, JPN6023035211, 2012, pages 5517 - 5522, ISSN: 0005138995 * |
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 30, no. 4, JPN6023035212, 2015, pages 152 - 159, ISSN: 0005138996 * |
THER ADV MED ONCOL, vol. 10, JPN6023035213, 2018, pages 1 - 11, ISSN: 0005138997 * |
Also Published As
Publication number | Publication date |
---|---|
US11357874B2 (en) | 2022-06-14 |
EP3923952A1 (en) | 2021-12-22 |
EP3923952A4 (en) | 2023-08-30 |
WO2020056064A1 (en) | 2020-03-19 |
US20200085979A1 (en) | 2020-03-19 |
US20200085981A1 (en) | 2020-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pauwels et al. | The mechanism of accumulation of tumour-localising radiopharmaceuticals | |
JP2020040992A (ja) | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 | |
KR20210087938A (ko) | Cd8 이미징 구조체 및 이의 사용 방법 | |
Jacobson et al. | Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics | |
JP7482180B2 (ja) | 癌のための併用療法 | |
Iikuni et al. | Radiotheranostics using a novel 225Ac-labeled radioligand with improved pharmacokinetics targeting prostate-specific membrane antigen | |
JP2023546679A (ja) | がん治療における放射免疫療法とcd47遮断の併用 | |
Lin et al. | Approach to the treatment of a patient with an aggressive pituitary tumor | |
CN115379848A (zh) | 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂 | |
Tsuchihashi et al. | Development of novel 111In/225Ac-labeled agent targeting PSMA for highly efficient cancer radiotheranostics | |
JP2022500464A (ja) | Her2+癌および他の新生物の標的放射性核種治療および分子イメージング及び精密治療 | |
van der Veldt et al. | Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance | |
AU2004292933B2 (en) | Targeting of Erb antigens | |
Heskamp et al. | Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring | |
JPWO2020056064A5 (ja) | ||
Ma et al. | Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers | |
WO2018226971A1 (en) | Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery | |
Vallabhajosula | Molecular Imaging in Oncology | |
CA3231129A1 (en) | Method for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a compound targeting cck2-r, and compound for use in methods of selectively treating and/or imaging cancer | |
Vallabhajosula | Theranostics in Prostate Cancer | |
Zeven et al. | Advancements in Nuclear Imaging Using radiolabeled Nanobody tracers to support Cancer Immunotherapy | |
WO2024107762A2 (en) | Decreased retention of miniproteins in kidney | |
Wynter et al. | ImmunoPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential | |
Muzaffar et al. | Nuclear Oncology | |
Theranostics | EXPLOITING RADIOLIGAND THERAPY-INDUCED IMMUNOMODULATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220912 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220912 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240326 |